贝那利珠单抗治疗哮喘和慢阻肺嗜酸性粒细胞急性加重(ABRA):双盲双模拟活性安慰剂对照随机试验
ABRA试验为多中心2期双盲双模拟活性安慰剂对照随机试验,纳入158例血嗜酸性粒细胞≥300/μL的哮喘或慢阻肺急性加重成人,比较贝那利珠单抗联合或不联合泼尼松龙与单用泼尼松龙。
要点
- 贝那利珠单抗可降低嗜酸性粒细胞急性加重90天治疗失败率。
- 联合贝那利珠单抗改善28天VAS症状,优于单用泼尼松龙。
- 贝那利珠单抗耐受良好,无致死性不良事件。
核心结论
- 贝那利珠单抗可用于治疗嗜酸性粒细胞急性加重,效果优于单用泼尼松龙的标准治疗。
- 结果为哮喘和慢阻肺嗜酸性粒细胞内型急性加重提供了新的治疗方式。
研究设计与样本
- ABRA为多中心2期双盲双模拟活性安慰剂对照随机试验,在英国两家医院完成。
- 从急诊和紧急护理诊所招募血嗜酸性粒细胞≥300/μL的哮喘或慢阻肺急性加重成人。
- 158例患者按1:1:1随机分配至泼尼松龙30mg每日一次5天联合贝那利珠单抗100mg皮下注射一次组、安慰剂片联合贝那利珠单抗100mg组或泼尼松龙30mg联合安慰剂皮下注射组。
- 共同主要结局为90天治疗失败比例和28天总VAS症状,在意向治疗人群中分析。
主要发现
- 无致死性不良事件,贝那利珠单抗耐受良好;高血糖和鼻窦炎或鼻窦感染不良事件仅与泼尼松龙研究药物相关。
关键数值与推荐
- 纳入标准为哮喘或慢阻肺急性加重且血嗜酸性粒细胞≥300个/μL的成人。
- 泼尼松龙方案为30mg每日一次口服5天,贝那利珠单抗为100mg皮下注射一次。
- 共同主要结局为90天治疗失败比例和28天总VAS症状。
临床怎么用
- 对血嗜酸性粒细胞≥300/μL的哮喘或慢阻肺急性加重患者,可考虑单次贝那利珠单抗治疗。
- 贝那利珠单抗可单独或联合泼尼松龙使用,以降低治疗失败风险并改善症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Exacerbations of asthma and chronic obstructive pulmonary disease (COPD) are important events and are associated with critical illness. Eosinophilic inflammation is a treatable trait commonly found during acute exacerbations of asthma and COPD. We hypothesised that for patients with eosinophilic exacerbations, a single injection of benralizumab, a humanised monoclonal antibody against interleukin-5 receptor-α, alone or in combination with prednisolone, will improve clinical outcomes compared with prednisolone, the standard of care. METHODS: The Acute exacerbations treated with BenRAlizumab trial (ABRA) was a multicentre, phase 2, double-blind, double-dummy, active placebo-controlled randomised trial completed in the UK at Oxford University Hospitals NHS Foundation Trust and Guy's and St Thomas' NHS Foundation Trust. Patients were recruited from urgent care clinics and emergency departments of these two hospitals. At the time of an acute exacerbation of asthma or COPD, adults with blood eosinophil counts of equal to or more than 300 cells per μL were randomly assigned in a 1:1:1 ratio to receive acute treatment with: prednisolone 30 mg once daily for 5 days and 100 mg benralizumab subcutaneous injection once (BENRA plus PRED group); placebo tablets once daily for 5 days and 100 mg benralizumab subcutaneous injection once (BENRA group); or prednisolone 30 mg once daily for 5 days and placebo subcutaneous injection once (PRED group). Randomisation was performed with a centralised interactive computer randomisation service. All patients and study research staff involved in data collection were masked to study blood results and treatment allocation. The co-primary outcomes were proportion of treatment failures over 90 days and total visual analogue scale (VAS) symptoms at day 28 in the pooled benralizumab groups compared with the prednisolone alone group and analysed in the intention-to-treat population. The trial was registered on Clinicaltrials.govNCT04098718. FINDINGS: Between May 13, 2021, and Feb 5, 2024, 287 patients were screened for study inclusion. 129 were excluded due to not having an exacerbation captured or not meeting the eosinophil exclusion criteria. 158 patients were randomly assigned at acute eosinophilic exacerbation of asthma or COPD where 86 (54%) patients were female and 72 (46%) were male with a mean age of 57 years (range, 18-84). 53 patients were randomly assigned to the PRED group, 53 were randomly assigned to the BENRA group, and 52 were assigned to the BENRA plus PRED treatment group. At 90 days, treatment failures occurred in 39 (74%) of 53 in the PRED group, and 47 (45%) of 105 in the pooled-BENRA group (OR 0·26 [95% CI 0·13-0·56]; p=0·0005). The 28-day total VAS mean difference was 49 mm (95% CI 14-84; p=0·0065), favouring the pooled-BENRA group. There were no fatal adverse events and benralizumab was well tolerated. Notably, hyperglycaemia and sinusitis or sinus infection adverse events were related to the prednisolone study drug only. INTERPRETATION: Benralizumab can be used as a treatment of acute eosinophilic exacerbations and achieves better outcomes than the current standard of care with prednisolone alone. These results offer a new way of treating eosinophilic endotypes of asthma and COPD exacerbations. FUNDING: AstraZeneca.
引用
- Ramakrishnan, Russell, Mahmood, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med. 2024. PMID: 39615502. doi:10.1016/S2213-2600(24)00299-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。